Related Experiment Video

Updated: May 26, 2026

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine
09:15

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine

Published on: February 24, 2023

Ipilimumab and cancer immunotherapy: a new hope for advanced stage melanoma

Matthew Mansh1

  • 1Stanford University School of Medicine, Stanford, California 94305, USA. mmansh@stanford.edu

The Yale Journal of Biology and Medicine
|December 20, 2011
PubMed

Insights

The Food and Drug Administration (FDA) approved ipilimumab (Yervoy), a CTLA-4 blocking antibody, offering improved survival for metastatic melanoma patients. This marks a significant advance in cancer immunotherapy, demonstrating the potential of targeting T-cell regulation.

Area of Science:

  • Immunology
  • Oncology
  • Pharmacology

Background:

  • Metastatic melanoma is a lethal cancer with limited treatment options and rising incidence.
  • For decades, no therapies have significantly improved survival rates for advanced melanoma.
  • Cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) is a T-cell inhibitory receptor.

Purpose of the Study:

  • To review the history and research of CTLA-4 receptor function.
  • To present pre-clinical evidence supporting CTLA-4 blockade in cancer therapy.
  • To discuss recent clinical trials demonstrating ipilimumab's efficacy in metastatic melanoma.

Main Methods:

  • Literature review of CTLA-4 research.
  • Analysis of pre-clinical studies on CTLA-4 blockade.
  • Summary of human clinical trial data for ipilimumab.

Main Results:

  • Ipilimumab (Yervoy) is an FDA-approved CTLA-4 blocking antibody.
  • Clinical trials show ipilimumab extends survival in metastatic melanoma patients.
  • CTLA-4 blockade demonstrates efficacy in advanced melanoma treatment.

Conclusions:

  • Ipilimumab represents a breakthrough in treating metastatic melanoma.
  • Cancer immunotherapies targeting T-cell regulation show significant promise.
  • Ipilimumab highlights the developing field of cancer immunotherapy.
Keywords:
CTLA-4T-cellscancerdermatologyimmunologyimmunotherapyipilimumabmelanomaskin

More Related Videos

Multiplexed Immunofluorescence Analysis and Quantification of Intratumoral PD-1+ Tim-3+ CD8+ T Cells09:32

Multiplexed Immunofluorescence Analysis and Quantification of Intratumoral PD-1+ Tim-3+ CD8+ T Cells

Published on: February 8, 2018

Flow Cytometry-Based Isolation and Therapeutic Evaluation of Tumor-Infiltrating Lymphocytes in a Mouse Model of Pancreatic Cancer07:55

Flow Cytometry-Based Isolation and Therapeutic Evaluation of Tumor-Infiltrating Lymphocytes in a Mouse Model of Pancreatic Cancer

Published on: January 17, 2025

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Cancer Vaccines01:30

Cancer Vaccines

Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Skin Cancer01:30

Skin Cancer

Skin cancer is a type of cancer that occurs when there is an abnormal growth of skin cells, usually triggered by damage to the DNA within the skin cells. It is primarily caused by exposure to ultraviolet (UV) radiation from the sun or artificial sources like tanning beds. Skin cancer is the most common type of cancer worldwide, and its incidence continues to rise.
Basal Cell Carcinoma (BCC): BCC is the most common type of skin cancer, accounting for about 80% of cases. It typically develops in...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...